Enhanced blood pressure-lowering effect of olmesartan in hypertensive patients with chronic kidney disease-associated sympathetic hyperactivity: HONEST study

Journal of Clinical Hypertension

Volumn 15, Issue 8, 2013, Pages 555-561

  Kario, Kazuomi ^a   Saito, Ikuo ^b   Kushiro, Toshio ^c   Teramukai, Satoshi ^d   Mori, Yoshihiro ^e   Hiramatsu, Katsutoshi ^e   Kobayashi, Fumiaki ^e   Shimada, Kazuyuki ^f  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b KEIO UNIVERSITY   (Japan)

^c NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d KANAZAWA UNIVERSITY   (Japan)

^e DAIICHI SANKYO CO   (Japan)

^f Shin Oyama City Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

OLMESARTAN;

ADOLESCENT; ADULT; AGED; ALCOHOL CONSUMPTION; ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; BODY MASS; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COMORBIDITY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; ESSENTIAL HYPERTENSION; FEMALE; HOME MONITORING; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PATIENT ATTITUDE; PRIORITY JOURNAL; PULSE RATE; SMOKING; SYMPATHETIC NERVE; SYSTOLIC BLOOD PRESSURE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; FEMALE; FOLLOW-UP STUDIES; HEART RATE; HUMANS; HYPERTENSION; IMIDAZOLES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY, CHRONIC; SYMPATHETIC NERVOUS SYSTEM; TETRAZOLES; YOUNG ADULT;

EID: 84880721761     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/jch.12132     Document Type: Article

References (40)

1. Smith PA, Graham LN, Mackintosh AF, et al. Relationship between central sympathetic activity and stages of human hypertension. Am J Hypertens. 2004;17:217-222.
2. Kario K, Pickering TG, Umeda Y, et al. Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: a prospective study. Circulation. 2003;107:1401-1406.
3. Kario K, White WB. Early morning hypertension: what does it contribute to overall cardiovascular risk assessment? J Am Soc Hypertens. 2008;2:397-402.
4. Kario K. Morning surge in blood pressure and cardiovascular risk: evidence and perspectives. Hypertension. 2010;56:765-773.
5. Tuck ML, Stern N, Sowers JR. Enhanced 24-hour norepinephrine and renin secretion in young patients with essential hypertension: relation with the circadian pattern of arterial blood pressure. Am J Cardiol. 1985;55:112-115.
6. Palatini P, Julius S. Heart rate and the cardiovascular risk. J Hypertens. 1997;15:3-17.
7. Grassi G, Vailati S, Bertinieri G, et al. Heart rate as marker of sympathetic activity. J Hypertens. 1998;16:1635-1639.
8. Straznicky NE, Lambert EA, Lambert GW, et al. Effects of dietary weight loss on sympathetic activity and cardiac risk factors associated with the metabolic syndrome. J Clin Endocrinol Metab. 2005;90:5998-6005.
9. Tamaki S, Nakamura Y, Yoshino T, et al. The association between morning hypertension and metabolic syndrome in hypertensive patients. Hypertens Res. 2006;29:783-788.
10. Klein IH, Ligtenberg G, Neumann J, et al. Sympathetic nerve activity is inappropriately increased in chronic renal disease. J Am Soc Nephrol. 2003;14:3239-3244.
11. Ishikawa J, Hoshide S, Shibasaki S, et al. Relationship between morning hypertension identified by home blood pressure monitoring and brain natriuretic peptide and estimated glomerular filtration rate: the Japan Morning Surge 1 (JMS-1) Study. J Clin Hypertens (Greenwich). 2008;10:34-42.
12. Grassi G, Quarti-Trevano F, Seravalle G, et al. Early sympathetic activation in the initial clinical stages of chronic renal failure. Hypertension. 2011;57:846-851.
13. Siddiqi L, Joles JA, Grassi G, Blankestijn PJ. Is kidney ischemia the central mechanism in parallel activation of the renin and sympathetic system? J Hypertens. 2009;27:1341-1349.
14. Saito I, Kario K, Kushiro T, et al. Rationale, study design, baseline characteristics and blood pressure at 16 weeks in the HONEST Study. Hypertens Res. 2012;36:177-182.
15. Ogihara T, Kikuchi K, Matsuoka H, et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens Res. 2009;32:3-107.
16. Committee of CKD Initiative, Japanese Society of Nephrology. Clinical practice guidebook for diagnosis and treatment of chronic kidney disease. Clin Exp Nephrol. 2009;13:187-256.
17. Hozawa A, Ohkubo T, Kikuya M, et al. Prognostic value of home heart rate for cardiovascular mortality in the general population: the Ohasama study. Am J Hypertens. 2004;17:1005-1010.
18. Fox K, Ford I, Steg PG, et al; BEAUTIFUL Investigators. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomized controlled trial. Lancet. 2008;372:817-821.
19. Grassi G. Assessment of sympathetic cardiovascular drive in human hypertension: achievements and perspectives. Hypertension. 2009;54:690-697.
20. Julius S, Jamerson K. Sympathetics, insulin resistance and coronary risk in hypertension: the 'chicken-and-egg' question. J Hypertens. 1994;12:495-502.
21. Kuramoto K, Ichikawa S, Hirai A, et al. Azelnidipine and amlodipine: a comparison of their pharmacokinetics and effects on ambulatory blood pressure. Hypertens Res. 2003;26:201-208.
22. Hoshide S, Kario K, Ishikawa J, et al. Comparison of the effects of cilnidipine and amlodipine on ambulatory blood pressure. Hypertens Res. 2005;28:1003-1008.
23. Kario K, Ando S, Kido H, et al. The effects of the l/n-type calcium channel blocker (cilnidipine) on sympathetic hyperactive morning hypertension; results from achieve-one. J Clin Hypertens. 2013;15:133-142.
24. Ligtenberg G, Blankestijn PJ, Oey PL, et al. Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. N Engl J Med. 1994;340:1321-1328.
25. Klein IH, Ligtenberg G, Oey PL, et al. Enalapril and losartan reduce sympathetic hyperactivity in patients with chronic renal failure. J Am Soc Nephrol. 2003;14:425-430.
26. Neumann J, Ligtenberg G, Oey L, et al. Moxonidine normalizes sympathetic hyperactivity in patients with eprosartan-treated chronic renal failure. J Am Soc Nephrol. 2004;15:2902-2907.
27. Neumann J, Ligtenberg G, Klein IH, et al. Sympathetic hyperactivity in hypertensive chronic kidney disease patients is reduced during standard treatment. Hypertension. 2007;49:506-510.
28. Siddiqi L, Oey PL, Blankestijn PJ. Aliskiren reduces sympathetic nerve activity and blood pressure in chronic kidney disease patients. Nephrol Dial Transplant. 2011;26:2930-2934.
29. Ye S, Ozgur B, Campese VM. Renal afferent impulses, the posterior hypothalamus, and hypertension in rats with chronic renal failure. Kidney Int. 1997;51:722-727.
30. Reid IA. Interactions between ANG II, sympathetic nervous system, and baroreceptor reflexes in regulation of blood pressure. Am J Physiol. 1992;262:E763-E778.
31. Williams JL, Barnes KL, Bronsnihan KM, Ferrario CM. Area postrema: a unique regulator of cardiovascular function. News Physiol Sci. 1992;7:30-34.
32. Kumagai H, Oshima N, Matsuura T, et al. Importance of rostral ventrolateral medulla neurons in determining efferent sympathetic nerve activity and blood pressure. Hypertens Res. 2012;35:132-141.
33. Sakata K, Kumagai H, Osaka M, et al. Potentiated sympathetic nervous and renin-angiotensin systems reduce nonlinear correlation between sympathetic activity and blood pressure in conscious spontaneously hypertensive rats. Circulation. 2002;106:620-625.
34. Matsuura T, Kumagai H, Kawai A, et al. Rostral ventrolateral medulla neurons of neonatal Wistar-Kyoto and spontaneously hypertensive rats. Hypertension. 2002;40:560-565.
35. Brooks VL, Haywood JR, Johnson AK. Translation of salt retention to central activation of the sympathetic nervous system in hypertension. Clin Exp Pharmacol Physiol. 2005;32:426-432.
36. Yano Y, Hoshide S, Etoh T, et al. Synergistic effect of chronic kidney disease and high circulatory norepinephrine level on stroke risk in Japanese hypertensive patients. Atherosclerosis. 2011;219:273-279.
37. Zoccali C, Leonardis D, Enia G, et al. Heart rate, age and the risk of progression to kidney failure in patients with CKD. J Nephrol. 2012;25(suppl 19):20-27.
38. Beddhu S, Nigwekar SU, Ma X, Greene T. Associations of resting heart rate with insulin resistance, cardiovascular events and mortality in chronic kidney disease. Nephrol Dial Transplant. 2009;24:2482-2488.
39. Neal B, MacMahon S, Chapman N; Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet. 2000;356:1955-1964.
40. Ukena C, Mahfoud F, Spies A, et al. Effects of renal sympathetic denervation on heart rate and atrioventricular conduction in patients with resistant hypertension. Int J Cardiol. 2012;Aug 20. doi:10.1016/j.ijcard.2012.07.027 [Epub ahead of print].